经过20年的肺炎球菌结合剂疫苗使用后侵袭性肺炎球菌病
Inci Yildirim1,2,3,4, Rotem Lapidot5,6, Yazdani Basha Shaik-Dasthagirisaheb6
1Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, Connecticut.
在引入肺炎球菌合疫苗 (PCV7和PCV13) 后的20年里,儿童的侵入性肺炎球菌病 (IPD) 发病率显著下降了72%. 监测发现了主导血清型的变化和抗菌素耐药性的下降.
科学领域:
- 儿童传染病 儿童传染病
- 疫苗学 疫苗学 疫苗学
- 流行病学 流行病学
背景情况:
- 侵入性肺炎球菌病 (IPD) 仍然是儿童的重大公共卫生问题.
- 引入肺炎球菌合疫苗 (PCV7和PCV13) 的目的是减少IPD的负担.
- 了解IPD不断变化的流行病学对于公共卫生战略至关重要.
研究的目的:
- 描述20年来马萨诸塞州儿童IPD流行病学的变化.
- 评估PCV7和PCV13疫苗实施对IPD发病率和血清型分布的影响.
- 为了监测Streptococcus pneumoniae分离物的抗微生物敏感性模式.
主要方法:
- 一个基于人口的监测系统从2002年到2021年跟踪了儿童 (<18岁) 的IPD病例.
- 单独的Streptococcus pneumoniae被血清型化并测试了对抗菌素敏感性的测试.
- 发病率和发病率比率是为了评估趋势而计算的.
主要成果:
- 在2002年至2021年期间,儿童的IPD总体发病率下降了72%.
- 在PCV13取代PCV7后,病率继续下降,在2020-2021年期间达到最低点.
- 观察到主导血清型的变化,非PCV13血清型变得越来越普遍,并显示出增加的青素不敏感性.
结论:
- 持续监测对于检测新出现的IPD血清型至关重要.
- 疫苗开发需要考虑循环肺炎球菌株的变化.
- 持续的监测为疫苗政策和公共卫生干预提供了信息.
更多相关视频
06:06Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
相关概念视频
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
